



## **XDx Receives Qualifying Therapeutic Discovery Project Award Funding**

We are happy to announce that XDx has received two grants totaling more than \$489,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program. The grants will support XDx's research into the comparative effectiveness of AlloMap versus biopsy and efforts to develop a molecular diagnostic for lupus.

"We are pleased to receive these grants and to have our unique capabilities recognized at the federal level," said Pierre Cassigneul, president and chief executive officer of XDx. "These awards recognize the value of our technology and the impact it can have on patients. This grant funding will help us further pursue our vision of developing non-invasive tests that improve patient quality of life."

As part of the Patient Protection and Affordable Care Act of 2010, these grants are being distributed to U.S. companies with fewer than 250 employees whose research shows the greatest potential to significantly advance the goal of curing cancer within 30 years; that address areas of serious unmet medical need; that could prevent, detect or treat chronic or acute diseases and conditions; that demonstrate the greatest potential to create and sustain high-quality, high-paying U.S. jobs; and to advance U.S. competitiveness in life, biological and medical sciences, as well as research that promises to reduce the long-term growth of health care costs in the U.S.